Atorvastatin Dosis Tinggi Jangka Pendek Untuk Pencegahan Nefropati Yang Dicetuskan Oleh Kontras Pada Pasien Angina Pektoris Stabil Yang Menjalani Intervensi Koroner Perkutan
i65
Daftar Pustaka
Andra CA, Hasan R, Siregar AA. Peningkatan kadar kreatinin serum dalam 24 jam
pertama paska intervensi koroner di RSUP.H.Adam Malik Medan. 2010.6-57.
ASCM
Coronary
Artery
Disease
Risk
Factor
Thresholds.
Diunduh
dari
http://www.acefitness.org/pdfs/ASCM-CAD-Risk-Factor-Chart.pdf.
Aspelin P, Aubry P, Fransos SG, Strasser R, Willendbrock R, Berg KJ, et al.
Nephrotoxic effect in high-risk patients undergoing angiography. N Eng J
Med. 2003;9:348-491.
Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Eng J
Med. 2006;354:379-86.
Bartholomew BA, Harjal KJ, Dukkipati S, Boura JA, Yerkev MW, Glazier S. Impact
of nephropathy after percutaneous coronary intervention and a method for risk
stratification. Am J Cardiol.2004;93:1515-19.
Bartorelli AL, Marienzi G. Contrast induced neprropathy. J Interven Cardiol.
2008;21:71-85.
Bonetti PO, et al. Statin effect beyond lipid lowering: are they clinically relevant?.
Eur Heart J 2003;24:225-48.
Brinker JA, Davidson CJ, Laskey W. Preventing in hospital cardiac and renal
complications in high risk PCI patients. Eur Heart J Supp . 2005;7(Suppl
G):G13-G24.
Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical hasil akhirs for
contrast-induced nephropathy after percutaneous coronary intervention for
patients with normal serum creatinine. Ann Acad Med Singapore. 2010;3:37480.
Chong E, Poh KK, Shen L, Chai P, Tan HC. Diabetic patients with normal baseline
renal function re at increased risk of developing contrast-induced nephropathy
post- percutaneous coronary intervention. Singapore Med J. 2009;50:250-54.
Universitas Sumatera Utara
i66
Conen D, Buerkle G, Perruchoud AP, Buettner HJ, Mueller C. Hypertension is an
independent risk factor for contrast nephropathy after percutaneous coronary
intervention. International Journal Of Cardiology. 2006;110:237-41.\
Dangas G, et al. Contrast-induced nephropathy after percutaneous coronary
intervention in relationship to chronic kidney disease and hemodynamic
variables. AM J Cardiol 2005;95:13-9
Detrenis S, Meschi M, Musini S, Savazi G. Lights and shadows on the pathogenesis
of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant.
2005;20:1542-50.
Finn WF. The clinical and renal consequences of contrast-induced nephropathy.
Nephrol Dial Transplant. 2006;21:2-10.
Gami AS, Garovic VD. Contrast nephropathy after coronary angioplasty. Mayo Clin
Proc. 2004;79:211-19.
Ghani AA, Tohamy KY. Risk score for contrast induced nephropathy following
percutaneus
coronary
intervention.
Saudi
J
Kidney
Dis
Transpl.
2009;20(2):240-5.
Gleeson TG, Bulugahapitiya S. Contast induced nephropathy. AJR. 2004;183:167389.
Gueler F, et al. Postischemic acute renal failure is reduced by short-term statin
treatment treatment in a rat model. J Am Soc Nephrol 2002;13:2288-98.
Gruberg L, Mehran R, Dangas G. acute renal failure requiring dialysis after
percutaneou coronary interventions. Catheter Cardiovasc Interv. 2001;52:40916.
Gruberg L, Mintz GS, Mehran S, Dangas G, Lamsky J, Kent KM, et al. The
prognostic implications of further renal function deterioration within 48 h of
interventional coronary procedure in patients with pre-existent chronic renal
insufficiency. J Am Coll Cardol. 2000;36:1542-48.
Heyman SN, Rosen S, Rosenberger C. Renal parenchimal hypoxia, hypoxia
adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc
Nephrol. 2008;3:288- 96.
Universitas Sumatera Utara
i67
Heyman SN, Brezis M, Crowin RE. Radiocontrast media induced acute renal failure.
In: Schrier RW, ed. Disease of the kidney and tract. 8 th ed. Philadelphia:
LippincottWiliams & Wilkins; 2007,p.1099-120.
Karlsberg RP, et al. ACCF/AHA 2011 key data elements and definitions of a base
cardiovascular vocabulary for electronic health records. J Am Coll Cardiol
2011;8(2):202-22.
Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of
gender on incidence and hasil akhir of contrast-induced nephropathy after
percutaneou coronary intervention. J INvasuve Cardiol. 2003;15:18-22.
Lindsay J, et al. Percutaneous coronary intervention-associated nephropathy
foreshadow increased risk of late adverse event in patients with normal
baseline serum creatinine. Catheter Cardiovasc Interv 2003;9:338-43.
Lindsay J, et al. Causes of acute renal dysfunction after percutaneous coronary
intervention and comparison of late mortality rate with postprocedure rise of
cretinine kinase-MB versus rise of serum creatinine. Am J Cardiol
2005;95:786-89.
Macder M, Klein M, Fehr T, Rickii H. Contrast nephropathy : Review focusing on
prevention. J Am Coll Cardiol. 2004;44:1763-71.
Marenzi G, et al. Contrast-induced nephropathy in patients undergoing primary
angioplasty for acute myocaridal infarction. J Am Coll Cardiol 2004;44:178085.
McCullough PA, Wolyn R, Rocher LR, Levin RN, O’Neil WW. Acute renal failure
after coronary intervention : Incidence, risk factors, and relationship to
mortality. Am J Med. 1997;103:368-75.
McCullough PA. Contast induced acute kidney injury. J Am Coll Cardiol.
2008;51:1419-28.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M. A simple risk score
for prediction of contrast induced nephropathy after percutaneus coronary
intervention. J Am Coll Cardiol. 2004;44:1393-99.
Universitas Sumatera Utara
i68
Mehran R, Nikolsky E. Contast induced nephropathy : definition, epidemiology and
patients at risk. Kidney International.2006;69:S11-S15.
Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning
the
prevention
of
contast
induced
nephropathy.
Crit
Care
Med.
2006;34(8):2060-67.
Mujtaba SH, Ashraf T, Mahmood SN, Anjum Q. Assesment of renal insufficiency in
patients with normal serum cretinine levels undergoing angiography. JPMA
2010;60:915.
Murphy SW, Barret BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol.
2000;11:177-82.
Nash K, Hafezz A, Hou S. Hospital-acquired renal insuficiency. Am J Kidney Dis
2002;39:930-36.
National Cholesterol Education Program (NCEP). Expert panel on detection,
evaluation and treatment of high blood cholesterol in adult (Adult treatment
panel III). Circulation 2002;106:3143.
Nikolsky E, Mehran R, Turcot D, Amyong ED, Mintz GS, et al. Impact of chronic
kidney disease on prognosis of patients with diabetes mellitus treated with
percutaneous coronary intervention. Am J Cardiol. 2004;94:300-5.
Opie LH, Gersh BJ. Drugs for the heart.Saunders Elsevier. Philadelphia. 7th ed. 35161.
Patti G, et al. Short term, high dose torvastatin retreatment to prevent contrastinduced nephropathy in patients with acute coronary syndromes undergoing
percvutaneous coronary intervention. The ARMYDA-CIN Trial. Am J Cardiol
2011;108:1-7.
Person PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced
nephropathy. KidneyInterventional. 2005;68:14-22.
Ribicini F, Graziani M, Gambaro G, Pasoli P, Pigth M. et al. Early creatinine shifts
predict contrast-induced nephropathy and persistent renal damage after
angiography. The American Journal of Medicine 2010;123:755-63.
Universitas Sumatera Utara
i69
Rich MW, Crecellius CA. Incidence, risk fators, and clinical course of acute renal
insufficiency after cardiac catheterization in patients 70 years of age or older.
Arch Intern Med. 1990;150:1237-42.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and
prognostic importance of acute renal failure after percutaneou coronary
intervention. Circulation. 2002;105:2259-64.
Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al.
Nephrotoxicity of ionic and nonionic contrast media in 1196 patients:A
randomized trial. Kidney International. 1995;47:254-61.
Rohilla A, Rohilla S, Kumar A, Khan MU, Deep A. Pleiotropic effects of statins: A
boulevard to cardioprotection. Arabian Journal of Chemistry 2011.06.025.
Sadat U. Contrast-induced nephropathy: do statins offer protection?. Curr Opin
Cardiol 26:334-37.
Schillinger M, Haumer M, Mlekusch W, Schierka G, Ahmadi R, Minar E. Predicting
renal failure after ballon angioplasty in high-risk patients.J Endovasc Ther.
2001;8:609-14.
Shoukat S, Gowani SA, Jafferani A, Dhakam SH.Contrast-induced nephropathy in
patients undergoing percutaneou coronary intervention. Cardiology Research
and practice. 2010.
Slocum N, Moscucci M, Smith D, Aronow H, Dixon S, Share D. The changing
defenition of contrast induced nephropathy and its clinical implications:
insights from the blue cross blue shield of michigan cardiovascular consortium
(BMC2). J Am Coll Cardiol. 2010;55:A142.
Thomsen HS. Reducing the risk of contrast medium induced nephropathy.In:
Thomsen HS, ed. Medical radiology diagnostic imaging. Germany: SpringerVerlag; 2006,p.35-43.
Toprak O, Cirit M. Risk factor for contast induced nephropathy. Kidney Blood Press
Res.2006;29:84-93.
Ultramari FT, Loures bueno LDR, Da Cunha CLP, Pia de Andrade PM, Nercolini
DC, Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radiocontrast nephropathy
Universitas Sumatera Utara
i70
in patints with and without diabetes mellitus. Kidney International.
1994;45:259-65.
Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins.
Pharmacol Ther 2003;99:95-112.
Wong GTC, Irwin MG. Contast induced nephropathy. Br J Anesth. 2007:99;474-83.
Yoon HJ, Hur SH. Determination of safe contrast media dosage to estimated
glomerular filtration rate ratios to avoid contrast induced nephropathy after
elective percutaneous coronary intervention. Korean Circ J. 2011; 41:265-71.
Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular
injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int
2003;64:128-39.
Zhang BC, Li WM, Xu YW. High dose statin pretreatment for the prevention of
contrast-induced nephropathy: A meta analysis. Canadian Journal of
Cardiology 27(2011):851-58.
Universitas Sumatera Utara
Daftar Pustaka
Andra CA, Hasan R, Siregar AA. Peningkatan kadar kreatinin serum dalam 24 jam
pertama paska intervensi koroner di RSUP.H.Adam Malik Medan. 2010.6-57.
ASCM
Coronary
Artery
Disease
Risk
Factor
Thresholds.
Diunduh
dari
http://www.acefitness.org/pdfs/ASCM-CAD-Risk-Factor-Chart.pdf.
Aspelin P, Aubry P, Fransos SG, Strasser R, Willendbrock R, Berg KJ, et al.
Nephrotoxic effect in high-risk patients undergoing angiography. N Eng J
Med. 2003;9:348-491.
Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Eng J
Med. 2006;354:379-86.
Bartholomew BA, Harjal KJ, Dukkipati S, Boura JA, Yerkev MW, Glazier S. Impact
of nephropathy after percutaneous coronary intervention and a method for risk
stratification. Am J Cardiol.2004;93:1515-19.
Bartorelli AL, Marienzi G. Contrast induced neprropathy. J Interven Cardiol.
2008;21:71-85.
Bonetti PO, et al. Statin effect beyond lipid lowering: are they clinically relevant?.
Eur Heart J 2003;24:225-48.
Brinker JA, Davidson CJ, Laskey W. Preventing in hospital cardiac and renal
complications in high risk PCI patients. Eur Heart J Supp . 2005;7(Suppl
G):G13-G24.
Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical hasil akhirs for
contrast-induced nephropathy after percutaneous coronary intervention for
patients with normal serum creatinine. Ann Acad Med Singapore. 2010;3:37480.
Chong E, Poh KK, Shen L, Chai P, Tan HC. Diabetic patients with normal baseline
renal function re at increased risk of developing contrast-induced nephropathy
post- percutaneous coronary intervention. Singapore Med J. 2009;50:250-54.
Universitas Sumatera Utara
i66
Conen D, Buerkle G, Perruchoud AP, Buettner HJ, Mueller C. Hypertension is an
independent risk factor for contrast nephropathy after percutaneous coronary
intervention. International Journal Of Cardiology. 2006;110:237-41.\
Dangas G, et al. Contrast-induced nephropathy after percutaneous coronary
intervention in relationship to chronic kidney disease and hemodynamic
variables. AM J Cardiol 2005;95:13-9
Detrenis S, Meschi M, Musini S, Savazi G. Lights and shadows on the pathogenesis
of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant.
2005;20:1542-50.
Finn WF. The clinical and renal consequences of contrast-induced nephropathy.
Nephrol Dial Transplant. 2006;21:2-10.
Gami AS, Garovic VD. Contrast nephropathy after coronary angioplasty. Mayo Clin
Proc. 2004;79:211-19.
Ghani AA, Tohamy KY. Risk score for contrast induced nephropathy following
percutaneus
coronary
intervention.
Saudi
J
Kidney
Dis
Transpl.
2009;20(2):240-5.
Gleeson TG, Bulugahapitiya S. Contast induced nephropathy. AJR. 2004;183:167389.
Gueler F, et al. Postischemic acute renal failure is reduced by short-term statin
treatment treatment in a rat model. J Am Soc Nephrol 2002;13:2288-98.
Gruberg L, Mehran R, Dangas G. acute renal failure requiring dialysis after
percutaneou coronary interventions. Catheter Cardiovasc Interv. 2001;52:40916.
Gruberg L, Mintz GS, Mehran S, Dangas G, Lamsky J, Kent KM, et al. The
prognostic implications of further renal function deterioration within 48 h of
interventional coronary procedure in patients with pre-existent chronic renal
insufficiency. J Am Coll Cardol. 2000;36:1542-48.
Heyman SN, Rosen S, Rosenberger C. Renal parenchimal hypoxia, hypoxia
adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc
Nephrol. 2008;3:288- 96.
Universitas Sumatera Utara
i67
Heyman SN, Brezis M, Crowin RE. Radiocontrast media induced acute renal failure.
In: Schrier RW, ed. Disease of the kidney and tract. 8 th ed. Philadelphia:
LippincottWiliams & Wilkins; 2007,p.1099-120.
Karlsberg RP, et al. ACCF/AHA 2011 key data elements and definitions of a base
cardiovascular vocabulary for electronic health records. J Am Coll Cardiol
2011;8(2):202-22.
Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of
gender on incidence and hasil akhir of contrast-induced nephropathy after
percutaneou coronary intervention. J INvasuve Cardiol. 2003;15:18-22.
Lindsay J, et al. Percutaneous coronary intervention-associated nephropathy
foreshadow increased risk of late adverse event in patients with normal
baseline serum creatinine. Catheter Cardiovasc Interv 2003;9:338-43.
Lindsay J, et al. Causes of acute renal dysfunction after percutaneous coronary
intervention and comparison of late mortality rate with postprocedure rise of
cretinine kinase-MB versus rise of serum creatinine. Am J Cardiol
2005;95:786-89.
Macder M, Klein M, Fehr T, Rickii H. Contrast nephropathy : Review focusing on
prevention. J Am Coll Cardiol. 2004;44:1763-71.
Marenzi G, et al. Contrast-induced nephropathy in patients undergoing primary
angioplasty for acute myocaridal infarction. J Am Coll Cardiol 2004;44:178085.
McCullough PA, Wolyn R, Rocher LR, Levin RN, O’Neil WW. Acute renal failure
after coronary intervention : Incidence, risk factors, and relationship to
mortality. Am J Med. 1997;103:368-75.
McCullough PA. Contast induced acute kidney injury. J Am Coll Cardiol.
2008;51:1419-28.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M. A simple risk score
for prediction of contrast induced nephropathy after percutaneus coronary
intervention. J Am Coll Cardiol. 2004;44:1393-99.
Universitas Sumatera Utara
i68
Mehran R, Nikolsky E. Contast induced nephropathy : definition, epidemiology and
patients at risk. Kidney International.2006;69:S11-S15.
Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning
the
prevention
of
contast
induced
nephropathy.
Crit
Care
Med.
2006;34(8):2060-67.
Mujtaba SH, Ashraf T, Mahmood SN, Anjum Q. Assesment of renal insufficiency in
patients with normal serum cretinine levels undergoing angiography. JPMA
2010;60:915.
Murphy SW, Barret BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol.
2000;11:177-82.
Nash K, Hafezz A, Hou S. Hospital-acquired renal insuficiency. Am J Kidney Dis
2002;39:930-36.
National Cholesterol Education Program (NCEP). Expert panel on detection,
evaluation and treatment of high blood cholesterol in adult (Adult treatment
panel III). Circulation 2002;106:3143.
Nikolsky E, Mehran R, Turcot D, Amyong ED, Mintz GS, et al. Impact of chronic
kidney disease on prognosis of patients with diabetes mellitus treated with
percutaneous coronary intervention. Am J Cardiol. 2004;94:300-5.
Opie LH, Gersh BJ. Drugs for the heart.Saunders Elsevier. Philadelphia. 7th ed. 35161.
Patti G, et al. Short term, high dose torvastatin retreatment to prevent contrastinduced nephropathy in patients with acute coronary syndromes undergoing
percvutaneous coronary intervention. The ARMYDA-CIN Trial. Am J Cardiol
2011;108:1-7.
Person PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced
nephropathy. KidneyInterventional. 2005;68:14-22.
Ribicini F, Graziani M, Gambaro G, Pasoli P, Pigth M. et al. Early creatinine shifts
predict contrast-induced nephropathy and persistent renal damage after
angiography. The American Journal of Medicine 2010;123:755-63.
Universitas Sumatera Utara
i69
Rich MW, Crecellius CA. Incidence, risk fators, and clinical course of acute renal
insufficiency after cardiac catheterization in patients 70 years of age or older.
Arch Intern Med. 1990;150:1237-42.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and
prognostic importance of acute renal failure after percutaneou coronary
intervention. Circulation. 2002;105:2259-64.
Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al.
Nephrotoxicity of ionic and nonionic contrast media in 1196 patients:A
randomized trial. Kidney International. 1995;47:254-61.
Rohilla A, Rohilla S, Kumar A, Khan MU, Deep A. Pleiotropic effects of statins: A
boulevard to cardioprotection. Arabian Journal of Chemistry 2011.06.025.
Sadat U. Contrast-induced nephropathy: do statins offer protection?. Curr Opin
Cardiol 26:334-37.
Schillinger M, Haumer M, Mlekusch W, Schierka G, Ahmadi R, Minar E. Predicting
renal failure after ballon angioplasty in high-risk patients.J Endovasc Ther.
2001;8:609-14.
Shoukat S, Gowani SA, Jafferani A, Dhakam SH.Contrast-induced nephropathy in
patients undergoing percutaneou coronary intervention. Cardiology Research
and practice. 2010.
Slocum N, Moscucci M, Smith D, Aronow H, Dixon S, Share D. The changing
defenition of contrast induced nephropathy and its clinical implications:
insights from the blue cross blue shield of michigan cardiovascular consortium
(BMC2). J Am Coll Cardiol. 2010;55:A142.
Thomsen HS. Reducing the risk of contrast medium induced nephropathy.In:
Thomsen HS, ed. Medical radiology diagnostic imaging. Germany: SpringerVerlag; 2006,p.35-43.
Toprak O, Cirit M. Risk factor for contast induced nephropathy. Kidney Blood Press
Res.2006;29:84-93.
Ultramari FT, Loures bueno LDR, Da Cunha CLP, Pia de Andrade PM, Nercolini
DC, Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radiocontrast nephropathy
Universitas Sumatera Utara
i70
in patints with and without diabetes mellitus. Kidney International.
1994;45:259-65.
Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins.
Pharmacol Ther 2003;99:95-112.
Wong GTC, Irwin MG. Contast induced nephropathy. Br J Anesth. 2007:99;474-83.
Yoon HJ, Hur SH. Determination of safe contrast media dosage to estimated
glomerular filtration rate ratios to avoid contrast induced nephropathy after
elective percutaneous coronary intervention. Korean Circ J. 2011; 41:265-71.
Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular
injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int
2003;64:128-39.
Zhang BC, Li WM, Xu YW. High dose statin pretreatment for the prevention of
contrast-induced nephropathy: A meta analysis. Canadian Journal of
Cardiology 27(2011):851-58.
Universitas Sumatera Utara